摘要
目的建立适合膀胱内灌注BCG的膀胱癌实验动物模型，观察重组hIFN-α-2b—BCG对其治疗效果。方法利用亚硝酸银化学损伤、MB49细胞移植改进方法，构建C57BL／6原位膀胱肿瘤小鼠模型，进行重组BCG和野生BCG灌注治疗，观察荷瘤小鼠生存率和苏木素-伊红（HE）染色后病理组织学变化，免疫组织化学检测p53。结果p53在荷瘤小鼠膀胱肿瘤表达强阳性。重组BCG和野生BCG各组灌注治疗后各重要器官组织未见肿瘤和结核结节形成。重组BCG灌注治疗组的小鼠平均膀胱重量（140．8±33．2）mg显著低于磷酸盐缓冲液（PBS）对照组的251．6±38．4，与野生型BCG治疗组的150．1±42．1、野生BCG＋IFN治疗组的144．6±39．7比较，差异无统计学意义（P〉0．05），但重组BCG治疗组的小鼠生存率高于野生型BCG治疗组。结论重组BCG小鼠原位膀胱肿瘤灌注治疗模型造模成功、肿瘤浸润迅速，恶性度高。重组hIFN-α-2b—BCG对小鼠体内膀胱肿瘤具有抑制肿瘤生长，影响肿瘤预后。
Objective To establish an animal model in vivo used for BCG perfusion of urinary bladder, and study the anti-tumor effect of recombinant hIFN-α-2b-BCG on bladder cancer. Methods The MB49 orthotopic murine bladder cancer models in C57BL/6 mice were established by chemical injury and MB49 cell transplantation to bladder. The inhibitory effect of recombinant BCG on the mice bearing tumor was studied by intravesical perfusion treatment. Tumor was certified by H-E stain and microscopy, and the expression of p53 detected by immunohistochemistry. Results p53 was positive in tested mice, suggesting the models with high-grade infiltration of cancer cells. In main organs, neither metastases nor TB nodules were found after perfusion of BCG. The results revealed that survival time in rBCG treatment mice was longer than that in wBCG group and wBCG ＋ IFN-α2b group （ P 〈 0.05 ）. Bladder weight （140. 8±33.2） mg in rBCG group was significantly lighter than 251.6 ±38.4 mg in the blank control group. There was no significant difference in bladder weight among the rBCG, wBCG, and wBCG ＋ IFN-α- 2b groups. Conclusion The orthotopic murine bladder cancer model was successfully established. Recombinant hIFN-α-2b-BCG has immuno-suppressive activity on the bladder tumor.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2010年第3期394-396,I0002,F0003,共5页
Chinese Journal of Experimental Surgery
基金
国家自然科学基金资助项目（30700834）
天津市科技支撑计划重大项目（07ZCKFSH03200）
国家科技部“十一五”重大专项新药创建课题（2009ZX09103-699）
